about
HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cellsFracture induced mobilization and incorporation of bone marrow-derived endothelial progenitor cells for bone healing.Local transplantation of human multipotent adipose-derived stem cells accelerates fracture healing via enhanced osteogenesis and angiogenesis.PlGF repairs myocardial ischemia through mechanisms of angiogenesis, cardioprotection and recruitment of myo-angiogenic competent marrow progenitorsLnk-dependent axis of SCF-cKit signal for osteogenesis in bone fracture healing.Bone marrow as a source of endothelial cells for natural and iatrogenic vascular repair.A small interfering RNA targeting Lnk accelerates bone fracture healing with early neovascularization.Vasculogenic conditioning of peripheral blood mononuclear cells promotes endothelial progenitor cell expansion and phenotype transition of anti-inflammatory macrophage and T lymphocyte to cells with regenerative potential.Transplantation of endothelial progenitor cells for therapeutic neovascularization.Therapeutic potential of vasculogenesis and osteogenesis promoted by peripheral blood CD34-positive cells for functional bone healing.Development of serum-free quality and quantity control culture of colony-forming endothelial progenitor cell for vasculogenesisRole of progenitor endothelial cells in cardiovascular disease and upcoming therapies.Endothelial progenitor cells for cardiovascular regenerationLocal transplantation of granulocyte colony stimulating factor-mobilized CD34+ cells for patients with femoral and tibial nonunion: pilot clinical trial.Phase II clinical trial of CD34+ cell therapy to explore endpoint selection and timing in patients with critical limb ischemia.Niche-dependent translineage commitment of endothelial progenitor cells, not cell fusion in general, into myocardial lineage cells.Intramyocardial transplantation of autologous endothelial progenitor cells for therapeutic neovascularization of myocardial ischemia.Estradiol enhances recovery after myocardial infarction by augmenting incorporation of bone marrow-derived endothelial progenitor cells into sites of ischemia-induced neovascularization via endothelial nitric oxide synthase-mediated activation of maEndothelial progenitor cells promote astrogliosis following spinal cord injury through Jagged1-dependent Notch signaling.Specific Jagged-1 signal from bone marrow microenvironment is required for endothelial progenitor cell development for neovascularization.Improvement of cardiac stem cell sheet therapy for chronic ischemic injury by adding endothelial progenitor cell transplantation: analysis of layer-specific regional cardiac function.Ischemic preconditioning upregulates vascular endothelial growth factor mRNA expression and neovascularization via nuclear translocation of protein kinase C epsilon in the rat ischemic myocardium.[Significance of retardation of abnormal uptake of iodine-123-beta-methyl-p-iodophenyl-pentadecanoic acid myocardial scintigraphy in patients with vasospastic angina]Vascular endothelial growth factor mRNA synthesis by peripheral blood mononuclear cells in patients with acute myocardial infarction.Human cardiac stem cells with reduced notch signaling show enhanced therapeutic potential in a rat acute infarction model.Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia.Sonic hedgehog myocardial gene therapy: tissue repair through transient reconstitution of embryonic signaling.Therapeutic superiority for cartilage repair by CD271-positive marrow stromal cell transplantation.Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction.Lnk deletion reinforces the function of bone marrow progenitors in promoting neovascularization and astrogliosis following spinal cord injury.Pivotal role of lnk adaptor protein in endothelial progenitor cell biology for vascular regeneration.[Carotid artery atherosclerosis in patients with myocardial infarction]Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.Superior Potential of CD34-Positive Cells Compared to Total Mononuclear Cells for Healing of Nonunion Following Bone Fracture.Differential activity of bone marrow hematopoietic stem cell subpopulations for EPC development and ischemic neovascularization.Therapeutic potential of unrestricted somatic stem cells isolated from placental cord blood for cardiac repair post myocardial infarction.CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis.Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia.Local transplantation of G-CSF-mobilized CD34(+) cells in a patient with tibial nonunion: a case report.Human peripheral blood CD34-positive cells enhance therapeutic regeneration of chronically injured liver in nude rats.
P50
Q28345589-83AF7942-D5B4-40E6-A7CB-8525278D1CE1Q33315418-2F00C344-CE19-47BE-9753-55686CD78998Q33531400-F722BECF-0C80-45A4-B9FE-B1F9F3EE22C2Q34039453-CE43B187-5CF9-4CFF-BD2E-816EE88F8729Q34161560-B167775A-D45B-4AA0-AEA4-28EF712F6DAAQ34497335-303E88DF-0D4C-4D5E-AC4E-9401A92DFB7FQ34880003-44FCC0F7-1FA9-4B7C-84FD-C709FEF8EF57Q35022016-62C35CFD-5EDC-4BA3-BE22-900D912C1BD9Q35218990-339A5EAC-E711-49DE-82EB-ADEBCE878565Q35222121-AE7F2F4E-F6DD-4917-972F-FD46D0A65F70Q36861476-12FA2740-395B-4125-ACAC-FABEE72765C8Q36951208-9EF90463-67A3-44F7-9117-C9038ADB7117Q37061004-F1EB415C-6104-4A57-8CAF-017FF042904FQ37516487-ACA8C993-BCC8-48B3-92EA-7092B36E6EE8Q38440905-71507C96-E3BA-46FA-8261-5BD0FE01C69FQ40429287-DCC7B763-6030-4565-8214-F8F1A782BAF1Q40608302-EAAF7786-77AC-4670-A0E4-622BC8555B8AQ42492012-674022E5-5285-46FD-AF93-D900D9400154Q42797685-E5C15D4A-F495-4B3C-B51B-D500EE38CE3CQ42811127-71A2B6EF-90B3-4C06-8B1E-8C1BE6D00690Q43511620-A4B849E8-CD53-4927-BA25-B33A0A5A46A4Q43576488-9357F02B-4C8C-4B71-A6B0-9E5650E020F8Q43701992-09DEAF4F-06BB-4936-AAE6-289900606B31Q43787128-0AB592B2-BE9E-4232-8915-5DC681C09CB5Q43991099-51D869A3-00B0-4086-BD15-B3E02B002345Q45877545-000B34F0-7DA8-4DB8-973D-7C459B370B4AQ45887964-F6A4EBDD-B3FE-4C6A-84A9-24CA4A1CE5EBQ46643273-040C4857-0BDD-4837-8F22-DFB1F91331E6Q48619654-A485C4D8-C7B8-450D-B200-76FE66010A84Q50723524-CBAE7F00-90E8-4E12-BC0A-7371E7D9646DQ50750627-4877BC4B-6550-457D-9CD9-D11192502269Q50851130-890873BC-BA61-4B61-93E6-7EED403A9DA0Q50981942-0AD1DB86-009A-4525-BD8D-1B201D7AF1F1Q51737339-33AE364C-34A7-4D3E-9F42-817F43F3C2A9Q51867950-DA3EDECC-0379-476D-8F76-A04E932BB08CQ51928322-8F00BD85-B824-4563-A7A0-CAE9DD62F852Q53057906-FB493CC5-F6D2-43FE-A45C-56C24F5BD33FQ53152319-A36638CD-B8AE-4092-8A5A-25E62374179DQ53254102-249A3401-0DCC-499C-9404-E48A50D12284Q54364473-DCCC8A63-11D1-4F66-BB3F-2B9F737F4CF7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Atsuhiko Kawamoto
@ast
Atsuhiko Kawamoto
@en
Atsuhiko Kawamoto
@es
Atsuhiko Kawamoto
@nl
type
label
Atsuhiko Kawamoto
@ast
Atsuhiko Kawamoto
@en
Atsuhiko Kawamoto
@es
Atsuhiko Kawamoto
@nl
prefLabel
Atsuhiko Kawamoto
@ast
Atsuhiko Kawamoto
@en
Atsuhiko Kawamoto
@es
Atsuhiko Kawamoto
@nl
P106
P21
P31
P496
0000-0002-2733-8015
P569
2000-01-01T00:00:00Z